LY2835219

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Breast NeoplasmsHealthy VolunteersLymphomaNeoplasm Metastasis

Phase 1

A Study of LY2835219 in Japanese Participants With Advanced Cancer

CompletedNCT02014129

Eli Lilly and CompanyLymphoma, Neoplasm Metastasis

Start: 2013-12-18End: 2019-08-21Updated: 2020-08-24

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Active, not recruitingNCT02057133

Eli Lilly and CompanyBreast Neoplasms

Start: 2014-03-10End: 2026-12-01Target: 198Updated: 2026-01-26

A Study of LY2835219 in Healthy Participants

CompletedNCT02059148

Eli Lilly and CompanyHealthy Volunteers

Start: 2014-02-28End: 2014-08-31Updated: 2019-01-07

A Study of LY2835219 in Healthy Participants

CompletedNCT02256267

Eli Lilly and CompanyHealthy Volunteers

Start: 2014-10-31End: 2014-11-30Updated: 2019-01-07

A Study of LY2835219 in Healthy Participants

CompletedNCT02327143

Eli Lilly and CompanyHealthy Volunteers

Start: 2015-01-31End: 2015-02-28Updated: 2018-08-06

Related Papers

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

UNC Libraries2022-03-29

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Frontiers in Oncology2022-02-1015 citations

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers.

2021-01-257 citations

A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.

2018-03-0148 citations

Abstract CT152: Food effect on the pharmacokinetics of 200-mg abemaciclib in healthy subject

Cancer Research2016-07-1511 citations

Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer

Cancer Research2016-02-156 citations

A phase Ib study of abemaciclib with therapies for metastatic breast cancer.

Journal of Clinical Oncology2015-05-2028 citations

MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).

Journal of Clinical Oncology2015-05-2017 citations